Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Subscribe To Our Newsletter & Stay Updated
